Marinus Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Marinus Pharma's estimated annual revenue is currently $15M per year.
- Marinus Pharma's estimated revenue per employee is $92,593
- Marinus Pharma's total funding is $238.1M.
Employee Data
- Marinus Pharma has 162 Employees.
- Marinus Pharma grew their employee count by 14% last year.
Marinus Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $43.2M | 215 | 6% | N/A | N/A |
#2 | $81.8M | 407 | 10% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 223 | 1% | N/A | N/A |
#6 | $13.1M | 65 | 5% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 86 | -5% | N/A | N/A |
#9 | $67.9M | 338 | 23% | N/A | N/A |
#10 | $14.9M | 74 | 7% | N/A | N/A |
What Is Marinus Pharma?
Marinus Pharmaceuticals is a development-stage pharmaceutical company focused on drugs to treat serious neurological and psychiatric disorders. SMRI will support work on a preclinical compound to treat bipolar disorder that has been in-licensed from Yale University.
keywords:N/A
$238.1M
Total Funding
162
Number of Employees
$15M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Marinus Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director, Marketing, Rare Genetic Epilepsy Franchise | Reveal Email/Phone |
2 | Regional Account Manager | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Senior Manager Financial Planning Analysis | Reveal Email/Phone |
5 | Manager Analytical Sciences | Reveal Email/Phone |
6 | Regional Account Manager | Reveal Email/Phone |
7 | Area Business Director | Reveal Email/Phone |
8 | Senior Director, Investor Relations | Reveal Email/Phone |
9 | Regional Account Manager | Reveal Email/Phone |
10 | VP, Strategy and Business Development | Reveal Email/Phone |
Marinus Pharma News
Marinus Pharma (MRNS) Reports Publication of ZTALMY Phase 3 Marigold Trial Results. April 14, 2022 7:03 AM. Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS)...
... Marinus Pharmaceuticals, Novartis, Neuren Pharmaceuticals, Roche, Confluence Pharmaceuticals, Tetra Therapeutics, Healx, and others.
March 18 (Reuters) - The U.S. health regulator has approved Marinus Pharmaceuticals Inc's (MRNS.O) lead drug to treat seizures associated...
Under the agreement, BARDA will fund up to $51 million of the $84 million contract for programs related to RSE development, including preclinical studies of IV ganaxolone in animal models and clinical development of the drug, including treatment of people exposed to nerve gas. Shares of Marinus ...
Other Companies in Radnor
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $28.9M | 181 | 0% | N/A |
#2 | $43.2M | 271 | -1% | N/A |
#3 | $86.8M | 463 | 8% | N/A |
#4 | $148M | 813 | -4% | N/A |
#5 | $396.7M | 1288 | 4% | N/A |